Trial reportInfection and immunity2002
Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria.
Trial report in Infection and immunity, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Vaccines for preventing malaria (blood-stage).The Cochrane database of systematic reviews · 2006Pooled it
- An engineered Plasmodium falciparum C-terminal 19-kilodalton merozoite surface protein 1 vaccine candidate induces high levels of interferon-gamma production associated with cellular immune responses to specific peptide sequences in Gambian adults naturally exposed to malaria.Clinical and experimental immunology · 2011Article
- Expression plasticity of Phlebotomus papatasi salivary gland genes in distinct ecotopes through the sand fly season.BMC ecology · 2011Article
- Measuring naturally acquired immune responses to candidate malaria vaccine antigens in Ghanaian adults.Malaria journal · 2011Article
- Differential cellular recognition of antigens during acute Plasmodium falciparum and Plasmodium vivax malaria.The Journal of infectious diseases · 2011Article
- Immunogenicity and in vitro protective efficacy of recombinant Mycobacterium bovis bacille Calmette Guerin (rBCG) expressing the 19 kDa merozoite surface protein-1 (MSP-1(19)) antigen of Plasmodium falciparum.Parasitology research · 2011Article
- Age-related differences in naturally acquired T cell memory to Plasmodium falciparum merozoite surface protein 1.PloS one · 2011Article
- Allele specificity of gamma interferon responses to the carboxyl-terminal region of Plasmodium falciparum merozoite surface protein 1 by Kenyan adults with naturally acquired immunity to malaria.Infection and immunity · 2010Article
- Schistosomiasis coinfection in children influences acquired immune response against Plasmodium falciparum malaria antigens.PloS one · 2010Article
- A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria.Journal of immunology (Baltimore, Md. : 1950) · 2009Article
- Immune responses of mice with different genetic backgrounds to improved multiepitope, multitarget malaria vaccine candidate antigen FALVAC-1A.Clinical and vaccine immunology : CVI · 2008Article
- Article
- Mannan-mediated gene delivery for cancer immunotherapy.Immunology · 2007Article
- Article
- Building better T-cell-inducing malaria vaccines.Immunology · 2005Review
- Comparison of immunogenicities of recombinant Plasmodium vivax merozoite surface protein 1 19- and 42-kiloDalton fragments expressed in Escherichia coli.Infection and immunity · 2004Article
- Top ten biotechnologies for improving health in developing countries.Nature genetics · 2002Article
- Immunogenetics and the design of Plasmodium falciparum vaccines for use in malaria-endemic populations.The Journal of clinical investigation · 2002Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 10 institutions in 6 countries.
Funding
Abstract
Plasmodium falciparum malaria is a major cause of death in the tropics. The 19-kDa subunit of P. falciparum merozoite surface protein 1 (MSP-1(19)), a major blood stage vaccine candidate, is the target of cellular and humoral immune responses in animals and humans. In this phase I trial of MSP-1(19), immunization of nonexposed human volunteers with either of the two allelic forms of recombinant MSP-1(19) induced high levels of antigen-specific Th1 (gamma interferon) and Th2 (interleukin 4 [IL-4] and IL-10) type lymphokines. The adjustment of the antigen dose and number of immunizations regulated the level of specificity of immune responses and Th1/Th2 bias of responses induced by vaccination. Novel conserved and allelic T-cell epitopes which induced cross-strain immune responses were identified. Importantly, responses to many of these novel epitopes were also present in adults exposed to malaria, both in east (Kenya) and west Africa (The Gambia). These data suggest that epitope-specific naturally acquired MSP-1(19) immune responses in endemic populations can be boosted by vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.